Skip to main content

Table 3 Treatment and follow up of patients with leishmaniasis included in this study

From: Imported cases of cutaneous leishmaniasis in Cuba, 2017: role of human movement

Case 17–01 (BW = 65.5 kg): Ampholip® (25 mg/day 1, 50 mg/day 2, and 150 mg/day 3 until 11), after 2 months Fluconazol® (300 mg/day during 30 days) and cutaneous lesion appears resoluted with negative PCR. One year later, appears new mucosal lesions and was treated with Ampholip® (300 mg/day 1 until 7), Fluconazol® (150/day during 37 days), and Ampholip® (300 mg/day during 7 days and 200 mg/day during 6 days). Finally, mucosal resolution was also observed with negative PCR and negative tomography of perinasal sinuses.
Case 17–02 (BW = 98 kg): Fluconazol® (300 mg/day during 15 days) in combination with Ampholip® (150 mg/days 7, 8, and 14). At this moment, resolution of lesion was observed with negative PCR.
Case 17–03 (BW = 100 kg): Amphotericin B® (10 mg/day 1, 20 mg/day 2, 30 mg/day 3, 40 mg/days 4, 5 and 6, and 50 mg/day 7), Fluconazol® (150 mg/day during 30 days) and 3 months later, other cycle of Fluconazol® (750 mg/week during 4 weeks). Ten months later, during reconsult patient received Ampholip® (300 mg/day during 5 days and day 14). After that, resolution of lesion was observed with negative PCR.
Case 17–04 (BW = 75 kg): Amphotericin B® (10 mg/day 1, 20 mg/day 3, 30 mg/days 4 and 5, and 40 mg/day 8). Fluconazol® (150 mg/day during 20 days). Clinical resolution was observed and patient did not return again to reconsult.
Case 17–05: Did not receive treatment due to the patient returned to origin country after diagnostic.